MENA MedTech Insights Podcast Por Ran Chen arte de portada

MENA MedTech Insights

MENA MedTech Insights

De: Ran Chen
Escúchala gratis

Welcome to MENA MedTech Insights, the definitive podcast for professionals in the Middle East and North Africa's rapidly growing medical technology sector. Each episode, we explore the latest innovations, market trends, and regulatory landscapes, featuring exclusive interviews with the founders, investors, and leaders who are shaping the future of healthcare in the region.Copyright 2026 Ran Chen Ciencia Ciencias Biológicas Economía
Episodios
  • Saudi AI MedTech Approval: Pure Global on Cracking the SFDA's New Cybersecurity Code.

    Saudi AI MedTech Approval: Pure Global on Cracking the SFDA's New Cybersecurity Code.
    Mar 27 2026
    In this episode of MENA MedTech Insights, we dissect last week's groundbreaking announcement from the Saudi Food and Drug Authority (SFDA). A new fast-track approval pathway has opened up for AI-powered medical devices, promising quicker access to the largest market in the Middle East by leveraging existing international clearances like the CE Mark and FDA approval. But this new opportunity comes with a hidden hurdle. The SFDA has simultaneously introduced stringent and mandatory cybersecurity requirements. We explore how this dual focus is creating a new set of challenges for manufacturers, shifting the regulatory burden from clinical efficacy to digital security and data integrity. Imagine you are a startup with a revolutionary AI diagnostic tool that just received its CE Mark. You're poised to enter the lucrative Saudi market ahead of your competition using the new fast-track system. However, your submission is rejected not on clinical grounds, but because your cybersecurity dossier lacks the specific threat modeling and post-market surveillance plans required by the SFDA. Every day of delay allows competitors to close the gap, potentially costing you first-mover advantage and significant revenue. What you'll learn in this episode: - What are the exact details of the SFDA's new fast-track pathway for AI medical devices? - How can leveraging existing FDA or CE approvals accelerate your entry into Saudi Arabia? - What are the critical, non-negotiable cybersecurity requirements in the new SFDA guidance? - Why is a local authorized representative more essential than ever to navigate these changes? - What are the most common mistakes that lead to rejection under this new framework? - How does this regulatory shift align with Saudi Arabia's broader Vision 2030 goals? - What does this move signal for the future of MedTech regulation across the entire GCC? Navigating these complex regulatory shifts is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local, in-market experts with advanced AI tools to streamline your global market access. From developing a regulatory strategy to compiling your technical dossier and ensuring post-market compliance, we are your partner in success. To learn more, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Más Menos
    2 m
  • Pure Global: Saudi Arabia's New MedTech Bundling Rule - A Market Access Hack or a Hidden Trap?

    Pure Global: Saudi Arabia's New MedTech Bundling Rule - A Market Access Hack or a Hidden Trap?
    Mar 26 2026
    This week on MENA MedTech Insights, we dissect a game-changing new regulation from the Saudi Food and Drug Authority (SFDA). The new device bundling guidance promises to slash costs and accelerate market access, but it's filled with hidden complexities that could trap unprepared manufacturers. We go beyond the headlines to reveal the strategic opportunities and the critical pitfalls. Imagine submitting your complete surgical kit in one application, only to face rejection because of a subtle misunderstanding of the term 'device family'. This costly mistake can set your launch back by months. We explore the nuances of this new rule to help you leverage it effectively. What you'll learn this episode: - What are the precise criteria for a 'device family' under the new SFDA bundling rule? - What is the single biggest mistake that leads to the rejection of a bundled submission? - Can you legally bundle diagnostic and therapeutic devices in a single application? - How can this new guidance potentially cut your product registration costs in half? - What specific documentation does the SFDA now require to justify a device bundle? - Is this the first step towards greater regulatory alignment between Saudi Arabia and the EU? - How do you build a bundling strategy that ensures first-pass approval? At Pure Global, we specialize in transforming complex regulatory updates into clear market-access strategies. Our local experts and AI-driven data tools provide the end-to-end support needed to navigate challenges like the SFDA's new bundling guidance, ensuring your entry into the Saudi market is both fast and compliant. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to secure your competitive edge.
    Más Menos
    2 m
  • Pure Global: Dubai's J&J Deal & The MedTech Strategy Beyond the Handshake

    Pure Global: Dubai's J&J Deal & The MedTech Strategy Beyond the Handshake
    Mar 25 2026
    This week on MENA MedTech Insights, we dissect the landmark Memorandum of Understanding signed between Dubai Health and Johnson & Johnson MedTech. This partnership is more than just a headline; it's a strategic maneuver that signals a major shift in how the region engages with global MedTech giants. We go beyond the press release to analyze what this collaboration means for market access, competition, and innovation in the UAE and beyond. The episode explores the new reality for other players in the market. A major deal gives a MedTech titan an inside track in Dubai, creating new challenges and opportunities for startups and scaleups. We discuss how companies without the backing of a government MoU can strategically navigate this increasingly competitive environment to successfully bring their innovations to the market. This week's key takeaways: - What does the J&J and Dubai Health deal signal about the future of public-private partnerships in the UAE? - How does a strategic government partnership impact the regulatory approval process for a multinational? - What are the three biggest challenges a smaller MedTech company now faces entering the Dubai market? - Are exclusive partnerships becoming the new standard for market entry in the Gulf? - How can you leverage 'innovation hub' initiatives to your advantage without a direct government MoU? - What specific technology areas is Dubai prioritizing for these types of deals? - How does this deal affect supply chain and distribution logistics in the region? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We help startups, scaleups, and multinationals navigate complex environments, develop regulatory strategies, and manage technical submissions to enter over 30 global markets, including key hubs like the UAE and Saudi Arabia. To learn how we can accelerate your market entry, contact us at info@pureglobal.com or visit https://pureglobal.com/.
    Más Menos
    2 m
Todavía no hay opiniones